Table 5.
Univariate and multivariate analyses of breast cancer‐specific survival in stages I–III breast cancer patients (n = 141)
| Variable | Univariate | Mutivariate | ||
|---|---|---|---|---|
| P‐value | Relative risk (95% CI) | P‐value | Relative risk (95% CI) | |
| miR‐1 status (positive/negative) | 0.0001 * | 11.74 (3.31–41.69) | 0.032 | 6.72 (1.18–38.37) |
| Ki‐67 LI** (1–98%) | 0.0002 * | 1.07 (1.04–1.11) | 0.43 | 1.02 (0.97–1.01) |
| PR status (positive/negative) | 0.0069 * | 0.58 (0.01–0.46) | 0.055 | 0.08 (0.01–1.06) |
| Histological grade (1,2/3) | 0.0083 * | 0.16 (0.04–0.63) | 0.47 | 2.24 (0.25–20.01) |
| pT (pT1/pT2‐4) | 0.011 * | 0.07 (0.01–0.54) | 0.13 | 0.13 (0.01–1.86) |
| ER status (positive/negative) | 0.013 * | 0.2 (0.06–0.071) | 0.98 | 1.02 (0.13–7.97) |
| Adjuvant endcrine therapy (received/not received) | 0.014 * | 0.21 (0.06–0.073) | 0.88 | 1.16 (0.18–7.49) |
| Lymph node metastasis (positive/negative) | 0.022 * | 6.12 (1.30–28.84) | 0.79 | 0.75 (0.09–6.21) |
| Ajuvant chemotherapy (received/not received) | 0.15 | 3.11 (0.66–14.63) | ||
| HER2 status (positive/negative) | 0.52 | 0.86 (0.18–4.04) | ||
Statistical analysis was evaluated by a proportional hazard model (Cox). P < 0.05 and 0.05 ≤ P < 0.10 were considered significant and borderline significant, and are listed in bold and italic respectively. *Significant (P < 0.05) and borderline‐significant (0.05 ≤ P < 0.10) values were examined in the multivariate analyses in this study. **Data were evaluated as continuous variables, and all other data were evaluated as dichotomized variables. 95% CI, 95% confidence interval.